It was also reported that TREM2 slowed AD progression and reduce tau-driven neurodegeneration by restricting the degree to which β-amyloid facilitates the spreading of pathogenic tau, which suggests an interplay among TREM2, tau pathology, and amyloid pathology [76]. This evidence concerns the gene MAPT and Alzheimer disease.